Sort
82,697 grants matching “vaccine development”
Core A: Administrative Core
$4,640,499Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2024 · AI
Core B: Data Management
$4,640,499George Golovko · University Of Texas Med Br Galveston · U19 · FY2024 · AI
Core D: Early and IND-Enabling Translational Research for Vaccines and MAbs
$4,640,499Larry Zeitlin · University Of Texas Med Br Galveston · U19 · FY2024 · AI
Core C: Microneedle Patch Vaccines
$4,640,499Louis D Falo · University Of Texas Med Br Galveston · U19 · FY2024 · AI
RP3: Cedar henipavirus animal model
$4,640,498Brian Schaefer · University Of Texas Med Br Galveston · U19 · FY2024 · AI
Core E: Animal Model Development and Preclinical Evaluation
$4,640,498Thomas William Geisbert · University Of Texas Med Br Galveston · U19 · FY2024 · AI
RP2: Vaccines and antibodies to henipavirus
$4,640,498Christopher Broder · University Of Texas Med Br Galveston · U19 · FY2024 · AI
RP1: Antigen design and testing of arenavirus and nairovirus
$4,640,498Robert W Cross · University Of Texas Med Br Galveston · U19 · FY2024 · AI
RP4: Monoclonal antibodies against henipaviruses, arenaviruses, and nairoviruses
$4,640,497James E Crowe · University Of Texas Med Br Galveston · U19 · FY2024 · AI
RP5: Nanobody therapeutics against henipaviruses, arenaviruses, and structural characterization
$4,640,497Kai Xu · University Of Texas Med Br Galveston · U19 · FY2024 · AI
SPECIFIC PATHOGEN FREE RHESUS MACAQUE BREEDING PROGRAM
$4,639,523Alpha Genesis, Inc. · U01 · FY2001 · AI
CoVPN 3004 - A Phase 3, Randomized, Observer-Blinded, Placebo-Controlled Study to Evaluate the Efficacy, Safety, and Immunogenicity of a SARS-CoV-2 Recombinant Spike Protein Nanoparticle Vaccine - LC3
$4,637,125Margaret Juliana McElrath · Fred Hutchinson Cancer Center · UM1 · FY2022 · AI
SOSIP-NP/mRNA combination for novel preventive and therapeutic HIV-1 vaccine regimens
$4,630,856Wilton B Williams · Duke University · UM1 · FY2025 · AI
Translating germline-targeting HIV Env SOSIP immunization of infants: targeting bnAbs in early life
$4,630,686Sallie R. Permar · Weill Medical Coll Of Cornell Univ · P01 · FY2025 · AI
Combined Immunologic Approaches to Cure HIV-1
$4,630,463Dan H. Barouch · Beth Israel Deaconess Medical Center · UM1 · FY2016 · AI
Combined Immunologic Approaches to Cure HIV-1
$4,630,463Dan H. Barouch · Beth Israel Deaconess Medical Center · UM1 · FY2017 · AI
Combined Immunologic Approaches to Cure HIV-1
$4,630,463Dan H. Barouch · Beth Israel Deaconess Medical Center · UM1 · FY2020 · AI
Combined Immunologic Approaches to Cure HIV-1
$4,630,463Dan H. Barouch · Beth Israel Deaconess Medical Center · UM1 · FY2018 · AI
SOUTH AFRICA MRC HIV PREVENTION TRIALS UNIT
$4,628,732Medical Research Council Of South Africa · U01 · FY2004 · AI
Infectious Diseases Research Technologies Core - RML
$4,626,642Robert Hohman · National Institute Of Allergy And Infectious Diseases · ZIC · FY2015 · AI
Conjugate nanoparticle platform development for HIV-1 envelope immunogens
$4,623,440Kevin O Saunders · Duke University · U19 · FY2025 · AI
Project 3: Vaccine Design [mRNA] VEEV/CHIKV (alphaviruses)
$4,622,541Jonathan R. Lai · Washington University · U19 · FY2024 · AI
Harvard University Center for AIDS Research
$4,620,425Bruce D Walker · Harvard University · P30 · FY2011 · AI
PanCorVac (Center for Pan-Coronavirus Vaccine Development)
$4,618,169Yoshihiro Kawaoka · University Of Wisconsin-Madison · P01 · FY2023 · AI
Natural History of AIDS in Homosexual Men
$4,616,765Roger Detels · University Of California Los Angeles · U01 · FY2017 · AI